Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 2/20 | 0.46 |
| ▸ | KDM4B | O94953 | 2/20 | 0.46 |
| ▸ | KDM5C | P41229 | 2/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16131370 | 0.81 | — | — | |
| SCHEMBL25048372 | 0.77 | CREBBP (0.44) | HSD11B1SPRHRH3USP30 | |
| SCHEMBL25731550 | 0.77 | HSD11B1 (0.44) | HSD11B1SPRHRH3USP30 | |
| SCHEMBL29338117 | 0.77 | HSD11B1 (0.44) | KDM4AKDM4BKDM5CKDM5BHSD11B1 | |
| SCHEMBL23108063 | 0.77 | HSD11B1 (0.44) | KDM4AKDM4BKDM5CKDM5BHSD11B1 | |
| SCHEMBL22415927 | 0.76 | KAT2B (0.43) | KDM4AKDM4BKDM5CKDM5BDRD2 | |
| SCHEMBL20009110 | 0.76 | HRH3 (0.52) | KDM4AKDM4BKDM5CKDM5BHSD11B1 | |
| SCHEMBL21733885 | 0.76 | CREBBP (0.45) | HSD11B1SPRUSP30HTT | |
| SCHEMBL26157325 | 0.75 | DRD2 (0.42) | KDM4AKDM4BKDM5CKDM5BDRD2 | |
| SCHEMBL24127247 | 0.74 | DRD2 (0.49) | DRD2USP30DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | KDM4A 1186/4885KDM4B 1082/4885KDM5C 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.